WallStreetZenWallStreetZen

NASDAQ: CARM
Carisma Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CARM past revenue growth

How has CARM's revenue growth performed historically?
Company
51.71%
Industry
154.55%
Market
17.87%
CARM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CARM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CARM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CARM earnings and revenue history

Current Revenue
$14.9M
Current Earnings
-$86.9M
Current Profit Margin
-582.3%

CARM Return on Equity

Current Company
-154%
Current Industry
-63.5%
Current Market
188%
CARM's Return on Equity (-154%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CARM announces earnings.

CARM Return on Assets

Current Company
-71.6%
Current Industry
2.9%
CARM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CARM Return on Capital Employed

Current Company
-120.6%
Current Industry
19.5%
CARM's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CARM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CARM$14.92M-$80.55M-$86.88M+68.95%N/A
GRTS$16.34M-$112.80M-$138.49M+68.96%N/A
TPST$0.00-$25.96M-$29.49MN/AN/A
CRVS$0.00-$26.88M-$27.03MN/AN/A
ANTX$0.00-$64.68M-$64.73MN/AN/A
View Top Biotech Stocks

CARM earnings dates

Next earnings date
May 9, 2024

Carisma Therapeutics Earnings & Revenue FAQ

What were CARM's earnings last quarter?

On Invalid Date, Carisma Therapeutics (NASDAQ: CARM) reported Q4 2023 earnings per share (EPS) of -$0.48, up 93.71% year over year. Total Carisma Therapeutics earnings for the quarter were -$20.96 million. In the same quarter last year, Carisma Therapeutics's earnings per share (EPS) was -$7.63.

If you're new to stock investing, here's how to buy Carisma Therapeutics stock.

What was CARM's earnings growth in the past year?

As of Q2 2024, Carisma Therapeutics's earnings has grown year over year. Carisma Therapeutics's earnings in the past year totalled -$86.88 million.

What is CARM's earnings date?

Carisma Therapeutics's earnings date is Invalid Date. Add CARM to your watchlist to be reminded of CARM's next earnings announcement.

What was CARM's revenue last quarter?

On Invalid Date, Carisma Therapeutics (NASDAQ: CARM) reported Q4 2023 revenue of $4.29 million up 14.96% year over year. In the same quarter last year, Carisma Therapeutics's revenue was $3.73 million.

What was CARM's revenue growth in the past year?

As of Q2 2024, Carisma Therapeutics's revenue has grown 51.71% year over year. This is 102.85 percentage points lower than the US Biotechnology industry revenue growth rate of 154.55%. Carisma Therapeutics's revenue in the past year totalled $14.92 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.